Valuation: Fate Therapeutics, Inc.

Market Cap 281M 247M 229M 211M 396M 27.05B 402M 2.72B 1.06B 13.3B 1.05B 1.03B 45.98B P/E 2026 *
-2.23x
P/E 2027 * -2.34x
Enterprise Value 281M 247M 229M 211M 396M 27.05B 402M 2.72B 1.06B 13.3B 1.05B 1.03B 45.98B EV / Sales 2026 *
53.5x
EV / Sales 2027 * 53.6x
Free-Float
98.83%
Yield 2026 *
-
Yield 2027 * -
1 day-4.37%
1 week-13.31%
Current month-10.74%
1 month+16.99%
3 months+81.20%
6 months+99.17%
Current year+145.27%
1 week 2.4
Extreme 2.4
2.89
1 month 1.86
Extreme 1.862
3.23
Current year 0.97
Extreme 0.97
3.23
1 year 0.91
Extreme 0.91
3.23
3 years 0.66
Extreme 0.6611
8.83
5 years 0.66
Extreme 0.6611
97.43
10 years 0.66
Extreme 0.6611
121.16
Manager TitleAgeSince
Chief Executive Officer 49 31/12/2024
Director of Finance/CFO 47 19/10/2025
Chief Operating Officer - 30/06/2021
Director TitleAgeSince
Chairman 78 30/11/2011
Director/Board Member 70 16/03/2014
Director/Board Member 47 30/07/2018
Date Insider Type Main position Quantity % Market Cap.
12/06/26 Free

Chairman

87,900 0.0754%
12/06/26 Free

Director

87,900 0.0754%
12/06/26 Free

Director

87,900 0.0754%
Change 5-day change 1-year change 3-year change Capi.($)
-4.37%-13.31%+92.80%-44.08% 281M
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -1.37%-0.18%+45.84%+149.45% 24.04B
Weighted average by Cap. -0.88%+2.08%+41.24%+135.48%

Financials

2026 *2027 *
Net sales 5.25M 4.61M 4.29M 3.93M 7.39M 505M 7.5M 50.89M 19.88M 248M 19.7M 19.27M 859M 5.24M 4.6M 4.28M 3.92M 7.37M 504M 7.49M 50.79M 19.84M 248M 19.66M 19.23M 857M
Net income -133M -117M -108M -99.42M -187M -12.77B -190M -1.29B -503M -6.28B -498M -487M -21.71B -148M -130M -121M -111M -208M -14.25B -212M -1.44B -561M -7B -555M -543M -24.22B
Net Debt - -
Logo Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.
Employees
161
Date Price Change Volume
24/07/26 US$2.410 -4.37% 1,044,435
23/07/26 US$2.520 -2.33% 1,637,234
22/07/26 US$2.580 -8.83% 1,499,137
21/07/26 US$2.830 +1.25% 1,143,679
20/07/26 US$2.795 +0.54% 1,456,549
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2.410USD
Average target price
5.411USD
Spread / Average Target
+124.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FATE Stock